KIF11 inhibitors are in Phase II trials for ovarian cancer14, and other adult advanced solid tumors14 such as breast, colorectal, renal, and lung cancers, head and neck squamous cell carcinoma, hepatocellular carcinoma and melanoma15, and Phase I trial for pediatric brain and solid tumors16,17. This evidence concerns the gene KIF11 and hepatocellular carcinoma.